DrugsControl Media Services

News Detail

SGLT2 inhibitors have ‘potential role’ in reducing cardiac, renal risks in lupus (16-11-2023)

SAN DIEGO, 15 NOV 2023: Patients with lupus who received sodium-glucose cotransporter-2 inhibitors demonstrated reduced risks for major adverse cardiovascular events and kidney disease, a speaker said at ACR Convergence 2023.


April Jorge, MD, View Details

Source : Healio Rheumatology
SGLT2 inhibitors

Related News